Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272531 · ClinicalTrials.gov registry record
Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)
A clinical trial of Bipolar Affective Disorder, sponsored by University of California, San Diego.
- Completed
- Registry status
- 560
- Enrollment target
- 10
- Study locations
NCT01272531 is a study of Bipolar Affective Disorder that has completed, run by University of California, San Diego. The registered enrollment target is 560 participants. The trial reports 10 study locations across 10 states.
The verdict
NCT01272531, a study of Bipolar Affective Disorder, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- 560 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.
Conditions Studied
Interventions
- DRUG Mood stabilizer treatment
Study Locations (10)
California
- University of California San Diego - San Diego
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan - Ann Arbor
Ohio
- University Hospitals Case Medical Center - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01272531
The ClinicalTrials.gov registry entry for NCT01272531 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Affective Disorder appearing as the primary indexed condition, and to 1 intervention - of which Mood stabilizer treatment is the first listed.
NCT01272531 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT01272531 about?
NCT01272531 is a clinical study titled "Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)". This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.
What is the current status of trial NCT01272531?
This trial is currently completed. The enrollment target is 560 participants. The study started on 2011-04. Estimated completion is 2016-04.
What conditions does trial NCT01272531 study?
This clinical trial studies the following conditions: Bipolar Affective Disorder.
What interventions are being tested in trial NCT01272531?
The interventions under investigation include: Mood stabilizer treatment (DRUG).
Who is sponsoring clinical trial NCT01272531?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01272531 being conducted?
This trial has 10 study locations across California, Illinois, Indiana, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.